

# BARD1 (1-300): sc-4355 WB

## BACKGROUND

Mutations within the BRCA1 gene, localized to chromosome 17q, are believed to account for approximately 45% of families with increased incidence of both early-onset breast cancer and ovarian cancer. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a RING domain near the N-terminus and appears to encode a tumor suppressor. BARD1 (BRCA1-associated RING domain protein 1) and BAP1 (BRCA1-associated protein 1) have both been shown to bind to the N-terminus of BRCA1 and are potential mediators of tumor suppression. BARD1 contains an N-terminal RING domain and three tandem ankyrin repeats. The C-terminus of BARD1 contains a region with sequence homology to BRCA1, termed the BRCT domain. BAP1 is a ubiquitin hydrolase and has been shown to enhance BRCA1-mediated cell growth suppression.

## REFERENCES

- Hall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B., and King, M. 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. *Science* 250: 1684-1689.
- Narod, S.A., Feunteun, J., Lynch, H.T., Watson, P., Conway, T., Lynch, J., and Lenoir, G.M. 1991. Familial breast-ovarian cancer locus on chromosome 17q12-q23. *Lancet* 338: 82-83.
- Novak, R. 1994. Breast cancer gene offers surprises. *Science* 265: 1796-1799.
- Futreal, P.A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L.M., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McClure, M., Frye, C., Weaver-Feldhaus, J., Ding, W., Gholami, Z., Söderkvist, P., Terry, L., Jhanwar, S., Berchuck, A., Igelhart, J.D., Marks, J., Ballinger, D.G., Barrett, J.C., Skolnick, M.H., Kamb, A., and Wiseman, R. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. *Science* 266: 120-122.
- Wu, L.C., Wang, Z.W., Tsan, J.T., Spillman, M.A., Phung, A., Xu, X.L., Yang, M.C., Hwang, L.Y., Bowcock, A.M., and Baer, R. 1996. Identification of a RING protein that can interact *in vivo* with the BRCA1 gene product. *Nat. Genet.* 14: 430-440.
- Jin, Y., Xu, X.L., Yang, M.C., Wei, F., Aji, T.C., Bowcock, A.M., and Baer, R. 1997. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. *Proc. Natl. Acad. Sci. USA* 94: 12075-12080.
- Thai, T.H., Du, F., Tsan, J.T., Jin, Y., Phung, A., Spillman, M.A., Massa, H.F., Muller, C.Y., Ashfaq, R., Mathis, J.M., Miller, D.S., Trask, B.J., Baer, R., and Bowcock, A.M. 1998. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. *Hum. Mol. Genet.* 7: 195-202.
- Jensen, D.E., Proctor, M., Marquis, S.T., Gardner, H.P., Ha, S.I., Chodosh, L.A., Ishov, A.M., Tommerup, N., Vissing, H., Sekido, Y., Minna, J., Borodovsky, A., Schultz, D.C., Wilkinson, K.D., Maul, G.G., Barlev, N., Prendergast, G.C., and Rauscher, F.J. III. 1998. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. *Oncogene* 16: 1097-1112.

## SOURCE

BARD1 (1-300) is expressed in *E. coli* as a 60 kDa tagged fusion protein corresponding to amino acids 1-300 of BARD1 of human origin.

## PRODUCT

BARD1 (1-300) is purified from bacterial lysates (>98%) by column chromatography; supplied as 10 µg in 0.1 ml SDS-PAGE loading buffer.

## APPLICATIONS

BARD1 (1-300) is suitable as a Western blotting control for sc-7373 and sc-11438.

## STORAGE

Store at -20° C; stable for one year from the date of shipment.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.